Central Serous Chorioretinopathy (CSC)

What Is Central Serous Chorioretinopathy?

Central serous chorioretinopathy (CSC) is a condition in which fluid from abnormally permeable blood vessels in the choroid (the vascular layer beneath the retina) leaks through the retinal pigment epithelium (RPE) and accumulates under the macula, causing a small, dome-shaped detachment of the central retina. CSC is the fourth most common retinopathy worldwide, after age-related macular degeneration, diabetic retinopathy, and branch retinal vein occlusion.

Unlike most retinal conditions, CSC primarily affects men between the ages of 30 and 50, with a male-to-female ratio of approximately 6 to 1. It is strongly associated with stress, Type A personality traits, and corticosteroid medications in any form.

Acute vs. Chronic CSC

The distinction between acute and chronic CSC is the most important factor in determining whether you need treatment.

Acute CSC

Acute CSC lasts less than 3–4 months and resolves spontaneously in 80–90% of cases without treatment. Most patients regain good visual acuity, though mild residual symptoms — slight distortion, reduced contrast sensitivity, or subtle dimming — frequently persist even after the fluid resolves. The main concern with acute CSC is recurrence: fluid returns in 30–50% of patients within the first year, and each recurrence increases the cumulative risk of developing chronic disease.

Chronic CSC

Chronic CSC persists beyond 3–4 months and carries a meaningful risk of permanent damage. When fluid sits beneath the retina for too long, the photoreceptor cells and RPE begin to deteriorate. Chronic CSC can lead to irreversible central vision loss in up to one-third of untreated cases. This is why most retina specialists recommend active treatment once CSC has persisted beyond 3–4 months or when imaging shows progressive damage to the retinal layers.

Common Symptoms

CSC often causes surprisingly mild visual disturbance relative to what’s happening inside the eye, which is why patients sometimes delay seeking care. The symptoms typically affect one eye.

• Blurred or hazy central vision in one eye.
• A dark, gray, or blurry spot in the center of your vision.
• Distorted vision — straight lines appearing curved or bent.
• Objects appearing smaller than normal in the affected eye (micropsia), caused by the fluid pushing photoreceptors apart.
• Dimming or reduced brightness in one eye, as though looking through a slightly dark filter.
• Colors appearing less vivid in the affected eye.

Important: The symptoms of CSC overlap substantially with conditions like wet AMD, retinal vein occlusion, and retinal detachment — all of which require different and often more urgent treatment. A retina specialist evaluation with imaging is the only way to confirm CSC and determine whether observation or treatment is appropriate.

Causes and Risk Factors

CSC is caused by abnormal leakiness of the choroidal blood vessels, which forces fluid through weak points in the RPE barrier and under the retina. Several factors significantly increase the risk.

• Corticosteroid use (most important modifiable risk factor): All forms of corticosteroids can trigger or worsen CSC — oral steroids, inhaled steroids (asthma inhalers), nasal sprays (allergy treatment), skin creams, and steroid injections. Patients are often surprised that their inhaler or nasal spray could affect their eyes. The odds ratio for CSC with systemic steroid use is 37.1.
• Psychological stress and Type A personality: CSC has a well-documented association with high stress, high-achievement personality traits, and high-stress occupations. Stress elevates cortisol levels, which increases choroidal blood vessel permeability.
• Male sex: Men are approximately 6 times more likely to develop CSC, likely related to androgen receptor expression in choroidal blood vessels.
• Age 30–50: The typical age range, with a mean onset around age 43.
• Exogenous testosterone therapy and obstructive sleep apnea: Both are associated with increased CSC risk and are modifiable.

Genetic predisposition and family history: In a study of families of patients with bilateral CSC, 52% had at least one affected relative.

How Is CSC Diagnosed?

CSC is diagnosed through a combination of clinical examination and multimodal imaging. At Retina Vision Consultants, we use several complementary technologies to confirm the diagnosis, distinguish CSC from conditions that look similar, and guide treatment decisions.

• Optical Coherence Tomography (OCT): The primary diagnostic and monitoring tool. OCT shows the dome-shaped collection of fluid beneath the retina and reveals RPE irregularities, photoreceptor integrity, and choroidal thickness — all critical for determining whether the condition is acute or chronic and assessing prognosis.
• Fluorescein Angiography (FA): Identifies the characteristic leakage patterns of CSC — the “inkblot” pattern (a focal leak that expands) and the “smokestack” pattern (an ascending column of dye). FA helps locate leakage points and distinguish acute from chronic disease.
• Indocyanine Green Angiography (ICGA): The most sensitive tool for characterizing the underlying choroidal abnormality. ICGA directly visualizes areas of choroidal hyperpermeability and is essential for guiding photodynamic therapy treatment — the laser is targeted at the areas of choroidal leakage identified on ICGA. ICGA availability is a meaningful differentiator for CSC care.
• Fundus Autofluorescence (FAF): Maps the health of the RPE, helping assess chronicity and the extent of RPE damage. In chronic CSC, characteristic “descending tracks” of RPE atrophy are visible.
• OCT-Angiography (OCTA): A non-invasive technique that can detect choroidal neovascularization (abnormal blood vessel growth), a complication that occurs in some chronic CSC cases and changes the treatment approach.

Treatment Options at RVC

Treatment depends on whether your CSC is acute or chronic, the location and severity of the leakage, and whether complications have developed.

Observation and Risk Factor Modification (For Acute CSC)

Because 80–90% of acute CSC resolves spontaneously within 3–4 months, the standard initial approach is watchful waiting with regular OCT monitoring every 4–6 weeks. If you are using any form of corticosteroid, stopping or reducing it — in coordination with your prescribing doctor — is the most important first step and may speed resolution. Addressing modifiable stress factors and sleep quality is also recommended.

Half-Dose Photodynamic Therapy (For Chronic CSC)

Half-dose verteporfin photodynamic therapy (PDT) is the current standard of care for chronic CSC. A photosensitizing medication (verteporfin) is infused intravenously, then a focused laser is applied to the areas of choroidal leakage identified on ICGA. The activated medication selectively reduces abnormal permeability, allowing the fluid to resolve. In clinical trials, 67–78% of patients achieved complete fluid resolution. The procedure is painless, performed in an outpatient setting, and most patients need only one session. Skin and eye photosensitivity lasts 48 hours after treatment.

Micropulse Laser Therapy

Micropulse laser delivers short, repetitive pulses of energy below the threshold for visible retinal damage, stimulating fluid resorption without creating permanent laser scars. It can treat near or at the fovea without risk of permanent foveal damage. Clinical trial evidence shows that half-dose PDT is more effective (67% vs. 29% complete resolution in the PLACE trial), but micropulse laser has a favorable safety profile and may be appropriate when PDT is not available or when there are contraindications.

Anti-VEGF Injections (For CSC With Neovascularization)

CSC itself is not a VEGF-driven disease, and anti-VEGF injections are not effective for uncomplicated CSC. However, chronic CSC can occasionally develop choroidal neovascularization (abnormal blood vessel growth) as a complication. When this occurs, anti-VEGF therapy is added to the treatment plan, typically alongside PDT.

Living With CSC: What to Expect

Will my vision recover? For acute CSC, the outlook is good — the vast majority of patients recover near-normal visual acuity once the fluid resolves, though subtle differences in contrast, brightness, or color between your eyes may persist. For chronic CSC treated with PDT, outcomes are generally favorable, with 67–78% achieving complete fluid resolution and meaningful visual improvement. However, the longer fluid has been present before treatment, the more likely some permanent photoreceptor damage has occurred.

What about recurrence? Recurrence is common — 30–50% of patients experience at least one recurrence within the first year. Avoiding corticosteroids in all forms and managing stress are the most important steps you can take to reduce recurrence risk. After resolution, you will typically be monitored with OCT at 1 month, 3 months, 6 months, and then every 6–12 months.

Your other eye: The choroidal abnormality underlying CSC is often present in both eyes, even when symptoms are only in one. Up to 40% of patients develop some involvement of the fellow eye over time. Both eyes will be evaluated at each visit.

Key lifestyle considerations: Avoid corticosteroids whenever possible and inform all your doctors about your CSC history before being prescribed steroids. Address modifiable stress factors, sleep quality, and sleep apnea if relevant.

When to See a Retina Specialist

If you have noticed new blurring, distortion, dimming, or a dark spot in the central vision of one eye — especially if you are a man between 30 and 55, under significant stress, or using any form of corticosteroid — schedule an evaluation with a retina specialist promptly. Do not wait for your next routine eye exam, as CSC symptoms overlap with conditions that require immediate treatment and only multimodal imaging can confirm the diagnosis.

Call Retina Vision Consultants at (310) 269-8565 to request an appointment.